Nephros, Inc.
NEPH
Positions held
Your positionsNEPH isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $35.73M | Enterprise value | $31.90M | Trailing P/E | 21.93 | Forward P/E | 15.67 |
| PEG | — | Price / book | 2.99 | Beta | 1.64 | Dividend yield | 0.00% |
| Revenue growth | 36.2% | Earnings growth | 450.0% | Gross margin | 61.3% | Operating margin | 20.2% |
| Profit margin | 8.4% | ROE | 16.1% | ROA | 7.3% | Debt / equity | 0.07 |
| Current ratio | 4.07 | Free cash flow | -$1.45M | Analyst recommendation | none | Mean target | $6.25 |
| 52w high | $6.42 | 52w low | $2.66 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $6.0M | $5.2M | $4.7M | $4.8M | $4.4M | — |
| Op margin | 20.2% | 1.9% | 0.4% | 6.6% | 5.6% | — |
| Net income | $1.2M | $0.1M | $0.1M | $0.3M | $0.2M | — |
| Gross margin | 66.9% | 57.4% | 58.4% | 61.2% | 63.2% | — |
| Gross profit | $4.0M | $3.0M | $2.8M | $2.9M | $2.8M | — |
| Operating income | $1.2M | $0.1M | $0.0M | $0.3M | $0.2M | — |
- Revenue +15% vs prior quarter ($6.0M vs $5.2M).
- Gross margin 66.9% (was 57.4% prior quarter).
- Operating margin expanded to 20.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $18.8M | $14.2M | $14.2M | $10.0M | — |
| Op margin | 6.1% | 0.0% | -11.2% | -43.5% | — |
| Net income | $1.2M | $0.1M | -$1.6M | -$7.4M | — |
| Gross margin | 61.9% | 61.6% | 59.0% | 47.4% | — |
| Gross profit | $11.6M | $8.7M | $8.4M | $4.7M | — |
| Operating income | $1.1M | $0.0M | -$1.6M | -$4.3M | — |
Headlines — positive tone
• [OK · fundamentals] Nephros Inc (NEPH) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge ...
News
2026-08-13 · Nephros (NEPH) Q2 2026 Earnings Call Transcript
2026-08-07 · Nephros, Inc. Q2 2026 Earnings Call Summary
2026-08-07 · Nephros Inc (NEPH) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge ...
2026-08-06 · Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026
2026-08-05 · Nephros Schedules Second Quarter 2026 Financial Results Conference Call
2026-07-17 · Northland Securities Initiates Coverage on Nephros With Market Perform Rating, $4 Price Target
Price (daily)
Full chart · RSI · MACD · patterns